New York Times
When Johnson & Johnson’s single-dose coronavirus vaccine was authorized for emergency use in late February, it was seen as a breakthrough for reaching vulnerable and isolated Americans, a crucial alternative to vaccines that require two shots weeks apart and fussier storage. It was soon popular on college campuses, in door-to-door campaigns and with harder-to-reach communities that often struggle with access to health care.
But with only 11.8 million doses administered in the United States so far — less than 4 percent of the total — the “one and done” vaccine has fallen flat. States have warned for weeks that they may not find recipients for millions of doses that will soon expire, partly because the vaccine’s appeal dropped after it was linked to a rare but serious blood-clotting disorder and injections were paused for 10 days in April.
READ FULL ARTICLE HERE > https://www.nytimes.com/2021/06/18/us/politics/johnson-johnson-covid-vaccine.html